Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Investigators determined the impact of socioeconomic status on disease status at presentation and survival among patients with head and neck squamous cell carcinoma.
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.
The timing of surgery taking place following an endometrial cancer diagnosis may adversely impact survival.
Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.
Weak social ties are associated with poorer survival and a higher risk of breast cancer recurrence, researchers say.
A new meta-analysis examines the impact of palliative care services on patients' and caregivers' quality of life and outcomes.
CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast CancerOctober 12, 2016
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.
The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.
Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.
HIV is associated with reduced cancer-specific survival among women with invasive cervical cancer.
Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple MyelomaAugust 16, 2016
The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).
Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.
Research indicates that metformin can confer improved survival for patients with colorectal cancer that also have diabetes.
Treatment with daratumumab, lenalidomide, and dexamethasone (DRd) may be superior to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.
Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
Use of androgen suppression therapy may negatively impact survival in African American patients with favorable-risk prostate cancer.
Survival among women age 40 years and younger with breast cancer appears to vary according to breast cancer subtype, with age particularly prognostic for women with luminal type breast cancers.
As salvage radiotherapy (SRT) outcomes may be affected by factors associated with prostatectomy findings, they may be positively affected when used at lower prostate-specific antigen (PSA) levels.
A very large retrospective study of patients with stage II colon cancer found adjuvant therapy improves survival, regardless of treatment regimen, patient age, or high-risk pathologic risk features.
Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.
Memory problems in breast cancer survivors appear associated with the high stress load these patients experience rather than their treatment, and moderate-to-vigorous physical activity may help subjective memory in these patients.
Lung cancers that manifest as nonsolid nodules seem to have indolent course, according to recent research data.
Many Older Women With Early Stage Breast Cancer Are Susceptible to Functional Decline After Starting TreatmentJuly 05, 2016
Approximately 20% of older women with stage I-III breast cancer lost the ability to complete some basic tasks of independent living within 1 year of starting treatment. However, an assessment tool can identify those women at greatest risk of posttreatment functional decline.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|